Reuters SG
** Novo Nordisk notched a win in its race to boost output of its popular obesity drug Wegovy, with its parent company announcing it was buying Catalent, a key manufacturing subcontractor of the product, for $16.5 billion. ** Brazilian fashion companies Arezzo & Co and Grupo Soma said they had agreed to a merger to form an entity with yearly revenues of 12 billion reais ($2.42 billion), which will be 54% controlled by Arezzo. ** Drug maker Novartis AG is in advanced talks to acquire MorphoSys AG, a developer of cancer treatments that has a market value of 1.6 billion euros ($1.7 billion), two people familiar with the matter said.